Histocompatibility. HLA and other systems.

Blood and Bone Marrow Pathology

Volumn , Issue , 2011, Pages 641-676

  Posch, P E ^a   Hurley, C K ^b  

^a GEORGETOWN UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84882507800     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1016/B978-0-7020-3147-2.00039-0     Document Type: Chapter

References (185)

1. Snell GD Studies in histocompatibility. Science 1981, 213:172-178.
2. Benacerraf B Role of MHC gene products in immune regulation. Science 1981, 212:1229-1238.
3. Dausset J The Nobel Lectures in Immunology. Lecture for the Nobel Prize for Physiology or Medicine, 1980. The major histocompatibility complex in man. Past, present, and future concepts. Science 1981, 213:1469-1474.
4. Groth CG, Brent LB, Calne RY, et al. Historic landmarks in clinical transplantation: Conclusions from the consensus conference at the University of California, Los Angeles. World J Surg 2000, 24:834-843.
5. Payne R, Tripp M, Weigle J, et al. A new leukocyte isoantigen system in man. Cold Spring. Harbor Symp Quant Biol 1964, 29:285-295.
6. van Rood JJ HLA and I. Annu Rev Immunol 1993, 11:1-28.
7. Bach FH, Hirschhorn K Lymphocyte interaction: a potential histocompatibility test in vitro. Science 1964, 143:813-814.
8. Thorsby E, Piazza A Joint report from the sixth international histocompatibility workshop conference. II. Typing for HLA-D determinants. Histocompatibility Testing 1975, 414-458. Munksgaard, Copenhagen. F. Kissmeyer-Nielsen .
9. Horton R, Gibson R, Coggill P, et al. Variation analysis and gene annotation of eight MHC haplotypes: the MHC Haplotype Project. Immunogenetics 2008, 60:1-18.
10. MHC Sequencing Consortium Complete sequence and gene map of a human major histocompatibility complex. Nature 1999, 401:921-923.
11. Beck S, Trowsdale J Sequence organization of the class II region of the human MHC. Immunol Rev 1999, 167:201-210.
12. Xie T, Rowen L, Aguado B, et al. Analysis of the gene-dense major histocompatibility complex class III region and its comparison to mouse. Genome Res 2003, 13:2621-2636.
13. Milner CM, Campbell RD Genetic organization of the human MHC class III region. Front Biosci 2001, 6:D914-D926.
14. Shiina T, Tamiya G, Oka A, et al. Genome sequence analysis of the 1.8Mb entire human MHC class I region. Immunol Rev 1999, 167:193-199.
15. Auffray C, Strominger JL Molecular genetics of the human major histocompatibility complex. Adv Hum Genet 1986, 15:197-247.
16. Kappes D, Strominger JL Human class II major histocompatibility complex genes and proteins. Annu Rev Biochem 1988, 57:991-1028.
17. Kwok WW, Kovats S, Thurtle P, Nepom GT HLA-DQ allelic polymorphisms constrain patterns of class II heterodimer formation. J Immunol 1993, 150:2263-2272.
18. Little A-M, Parham P Polymorphism and evolution of HLA class I and class II genes and molecules. Rev Immunogenetics 1999, 1:105-123.
19. Bontrop RE Comparative genetics of MHC polymorphisms in different primate species: duplications and deletions. Hum Immunol 2006, 67:388-397.
20. Marsh SG, Albert ED, Bodmer WF, et al. Nomenclature for factors of the HLA system, 2004. Tissue Antigens 2005, 65:301-369.
21. Robinson J, Waller MJ, Parham P, et al. IMGT/HLA and IMGT/MHC: sequence databases for the study of the major histocompatibility complex. Nucleic Acids Res 2003, 31:311-314.
22. Martin MP, Carrington M Immunogenetics of viral infections. Curr Opin Immunol 2005, 17:510-516.
23. Meyer D, Single RM, Mack SJ, et al. Signatures of demographic history and natural selection in the human major histocompatibility complex loci. Genetics 2006, 173:2121-2142.
24. Prugnolle F, Manica A, Charpentier M, et al. Pathogen-driven selection and worldwide HLA class I diversity. Curr Biol 2005, 15:1022-1027.
25. Yeager M, Hughes AL Evolution of the mammalian MHC: natural selection, recombination, and convergent evolution. Immunol Rev 1999, 167:45-58.
26. Cullen M, Perfetto SP, Klitz W, et al. High-resolution patterns of meiotic recombination across the human major histocompatibility complex. Am J Hum Genet 2002, 71:759-776.
27. Jeffreys AJ, Holloway JK, Kauppi L, et al. Meiotic recombination hot spots and human DNA diversity. Philos Trans R Soc Lond B Biol Sci 2004, 359:141-152.
28. Solberg OD, Mack SJ, Lancaster AK, et al. Balancing selection and heterogeneity across the classical human leukocyte antigen loci: a meta-analytic review of 497 population studies. Hum Immunol 2008, 69:443-464.
29. Maiers M, Gragert L, Klitz W High-resolution HLA alleles and haplotypes in the United States population. Hum Immunol 2007, 68:779-788.
30. Mori M, Beatty PG, Graves M, et al. HLA gene and haplotype frequencies in the North American population - the National Marrow Donor Program Donor Registry. Transplantation 1997, 64:1017-1027.
31. Begovich AB, Klitz W, Steiner LL, et al. HLA-DQ haplotypes in 15 different populations. The major histocompatibility complex: evolution, structure and function 2000, 412-426. Springer-Verlag, Tokyo. M. Kasahara .
32. Klitz W, Maiers M, Spellman S, et al. New HLA haplotype frequency reference standards: high-resolution and large sample typing of HLA DR-DQ haplotypes in a sample of European Americans. Tissue Antigens 2003, 62:296-307.
33. Yunis EJ, Larsen CE, Fernandez-Vina M, et al. Inheritable variable sizes of DNA stretches in the human MHC: conserved extended haplotypes and their fragments or blocks. Tissue Antigens 2003, 62:1-20.
34. Traherne JA, Horton R, Roberts AN, et al. Genetic analysis of completely sequenced disease-associated MHC haplotypes identifies shuffling of segments in recent human history. PLoS Genet 2006, 2:e9.
35. Van Den Elsen PJ, Holling TM, Kuipers HF, van der Stoep N Transcriptional regulation of antigen presentation. Curr Opin Immunol 2004, 16:67-75.
36. Van Den Elsen PJ, Gobin SJP, Van Eggermond MC, Peijnenburg A Regulation of MHC class I and II gene transcription: differences and similarities. Immunogenetics 1998, 48:208-221.
37. Mach B, Steimle V, Martinez-Soria E, Reith W Regulation of MHC class II genes: lessons from a disease. Annu Rev Immunol 1996, 14:301-331.
38. Muhlethaler-Mottet A, Krawczyk M, Masternak K, et al. The S box of major histocompatibility complex class II promoters is a key determinant for recruitment of the transcriptional co-activator CIITA. J Biol Chem 2004, 279:40529-40535.
39. Gobin SJ, van Zutphen M, Westerheide SD, et al. The MHC-specific enhanceosome and its role in MHC class I and beta-microglobulin gene transactivation. J Immunol 2001, 167:5175-5184.
40. Emery P, Mach B, Reith W The different level of expression of HLA-DRB1 and -DRB3 genes is controlled by conserved isotypic differences in promoter sequence. Hum Immunol 1993, 38:137-147.
41. Leën MPJM, Gorski J DRB4 promoter polymorphism in DR7 individuals: correlation with DRB4 pre-mRNA and mRNA levels. Immunogenetics 1997, 45:371-378.
42. Garcia-Lora A, Algarra I, Garrido F MHC class I antigens, immune surveillance, and tumor immune escape. J Cell Physiol 2003, 195:346-355.
43. Lilley BN, Ploegh HL Viral modulation of antigen presentation: manipulation of cellular targets in the ER and beyond. Immunol Rev 2005, 207:126-144.
44. Kaufmann SH, Schaible UE Antigen presentation and recognition in bacterial infections. Curr Opin Immunol 2005, 17:79-87.
45. Lin A, Xu H, Yan W Modulation of HLA expression in human cytomegalovirus immune evasion. Cell Mol Immunol 2007, 4:91-98.
46. Kimball ES, Coligan JE Structure of class I major histocompatibility antigens. Contemp Top Mol Immunol 1983, 9:1-63.
47. Adamashvili I, Kelley RE, Pressly T, McDonald JC Soluble HLA: patterns of expression in normal subjects, autoimmune diseases, and transplant recipients. Rheumatol Int 2005, 25:491-500.
48. Maenaka K, Jones EY MHC superfamily structure and the immune system. Curr Opin Struct Biol 1999, 9:745-753.
49. Madden DR The three-dimensional structure of peptide-MHC complexes. Annu Rev Immunol 1995, 13:587-622.
50. Stevanovic S Structural basis of immunogenicity. Transpl Immunol 2002, 10:133-136.
51. Hickman HD, Luis AD, Buchli R, et al. Toward a definition of self: proteomic evaluation of the class I peptide repertoire. J Immunol 2004, 172:2944-2952.
52. Jones EY, Fugger L, Strominger JL, Siebold C MHC class II proteins and disease: a structural perspective. Nat Rev Immunol 2006, 6:271-282.
53. Thorsby E, Lie BA HLA associated genetic predisposition to autoimmune diseases: genes involved and possible mechanisms. Transpl Immunol 2005, 14:175-182.
54. Hattotuwagama CK, Doytchinova IA, Flower DR Toward the prediction of class I and II mouse major histocompatibility complex-peptide-binding affinity: in silico bioinformatic step-by-step guide using quantitative structure-activity relationships. Methods Mol Biol 2007, 409:227-245.
55. Sturniolo T, Bono E, Ding J, et al. Generation of tissue-specific and promiscuous HLA ligand databases using DNA microarrays and virtual HLA class II matrices. Nat Biotechnol 1999, 17:555-561.
56. Nielsen M, Lundegaard C, Blicher T, et al. Quantitative predictions of peptide binding to any HLA-DR molecule of known sequence: NetMHCIIpan. PLoS Comput Biol 2008, 4:e1000107.
57. Stevanovic S, Lemmel C, Hantschel M, Eberle U Generating data for databases - the peptide repertoire of HLA molecules. Novartis Found Symp 2003, 254:143-155.
58. Lee KH, Wucherpfennig KW, Wiley DC Structure of a human insulin peptide-HLA-DQ8 complex and susceptibility to type 1 diabetes. Nat Immunol 2001, 2:501-507.
59. Zavala-Ruiz Z, Strug I, Anderson MW, et al. A polymorphic pocket at the P10 position contributes to peptide binding specificity in class II MHC proteins. Chem Biol 2004, 11:1395-1402.
60. Garbi N, Tanaka S, Van Den BM, et al. Accessory molecules in the assembly of major histocompatibility complex class I/peptide complexes: how essential are they for CD8 T-cell immune responses?. Immunol Rev 2005, 207:77-88.
61. Van Kaer L Major histocompatibility complex class I-restricted antigen processing and presentation. Tissue Antigens 2002, 60:1-9.
62. York IA, Chang SC, Saric T, et al. The ER aminopeptidase ERAP1 enhances or limits antigen presentation by trimming epitopes to 8-9 residues. Nat Immunol 2002, 3:1177-1184.
63. Serwold T, Gonzalez F, Kim J, et al. ERAAP customizes peptides for MHC class I molecules in the endoplasmic reticulum. Nature 2002, 419:480-483.
64. Pieters J MHC class II restricted antigen presentation. Curr Opin Immunol 1997, 9:89-96.
65. Gelin C, Sloma I, Charron D, Mooney N Regulation of MHC II and CD1 antigen presentation: from ubiquity to security. J Leukoc Biol 2009, 85:215-224.
66. Watts C The exogenous pathway for antigen presentation on major histocompatibility complex class II and CD1 molecules. Nat Immunol 2004, 5:685-692.
67. Brocke P, Garbi N, Momburg F, Hammerling GJ HLA-DM, HLA-DO and tapasin: functional similarities and differences. Curr Opin Immunol 2002, 14:22-29.
68. Karlsson L DM and DO shape the repertoire of peptide-MHC-class-II complexes. Curr Opin Immunol 2005, 17:65-70.
69. Alfonso C, Karlsson L Nonclassical MHC class II molecules. Annu Rev Immunol 2000, 18:113-142.
70. Kuhns MS, Davis MM, Garcia KC Deconstructing the form and function of the TCR/CD3 complex. Immunity 2006, 24:133-139.
71. Rudolph MG, Stanfield RL, Wilson IA How TCRs bind MHCs, peptides, and coreceptors. Annu Rev Immunol 2006, 24:419-466.
72. Armstrong KM, Piepenbrink KH, Baker BM Conformational changes and flexibility in T-cell receptor recognition of peptide-MHC complexes. Biochem J 2008, 415:183-196.
73. Gao GF, Rao Z, Bell JI Molecular coordination of alphabeta T-cell receptors and coreceptors CD8 and CD4 in their recognition of peptide-MHC ligands. Trends Immunol 2002, 23:408-413.
74. Rowen L, Koop BF, Hood L The complete 685-kilobase DNA sequence of the human β T cell receptor locus. Science 1996, 272:1755-1762.
75. Xiong N, Raulet DH Development and selection of gammadelta T cells. Immunol Rev 2007, 215:15-31.
76. Von Boehmer H Selection of the T-cell repertoire: receptor-controlled checkpoints in T-cell development. Adv Immunol 2004, 84:201-238.
77. Starr TK, Jameson SC, Hogquist KA Positive and negative selection of T cells. Annu Rev Immunol 2003, 21:139-176.
78. Maggi E, Cosmi L, Liotta F, et al. Thymic regulatory T cells. Autoimmun Rev 2005, 4:579-586.
79. Goldrath AW, Bevan MJ Selecting and maintaining a diverse T-cell repertoire. Nature 1999, 402:255-262.
80. Afzali B, Lombardi G, Lechler RI Pathways of major histocompatibility complex allorecognition. Curr Opin Organ Transplant 2008, 13:438-444.
81. Felix NJ, Allen PM Specificity of T-cell alloreactivity. Nat Rev Immunol 2007, 7:942-953.
82. Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, et al. High-resolution donor-recipient HLA matching contributes to the success of unrelated donor marrow transplantation. Blood 2007, 110:4576-4583.
83. Lindahl KF, Wilson DB Histocompatibility antigen-activated cytotoxic T lymphocytes. II. Estimates of the frequency and specificity of precursors. J Exp Med 1977, 145:508-522.
84. Archbold JK, Macdonald WA, Burrows SR, et al. T-cell allorecognition: a case of mistaken identity or deja vu?. Trends Immunol 2008, 29:220-226.
85. Gobin SJ, Van Den Elsen PJ Transcriptional regulation of the MHC class Ib genes HLA-E, HLA-F, and HLA-G. Hum Immunol 2000, 61:1102-1107.
86. Posch PE, Borrego F, Brooks AG, Coligan JE HLA-E is the ligand for the natural killer cell CD94/NKG2 receptors. J Biomed Sci 1998, 5:321-331.
87. Sullivan LC, Clements CS, Rossjohn J, Brooks AG The major histocompatibility complex class Ib molecule HLA-E at the interface between innate and adaptive immunity. Tissue Antigens 2008, 72:415-424.
88. Petrie EJ, Clements CS, Lin J, et al. CD94-NKG2A recognition of human leukocyte antigen -E bound to an HLA class I leader sequence. J Exp Med 2008, 205:725-735.
89. Hoare HL, Sullivan LC, Pietra G, et al. Structural basis for a major histocompatibility complex class Ib-restricted T cell response. Nat Immunol 2006, 7:256-264.
90. O'Callaghan CA, Bell JI Structure and function of the human class Ib molecules HLA-E, HLA-F and HLA-G. Immunol Rev 1998, 163:129-138.
91. Sullivan LC, Hoare HL, McCluskey J, et al. A structural perspective on MHC class Ib molecules in adaptive immunity. Trends Immunol 2006, 27:413-420.
92. Lepin EJ, Bastin JM, Allan DS, et al. Functional characterization of HLA-F and binding of HLA-F tetramers to ILT2 and ILT4 receptors. Eur J Immunol 2000, 30:3552-3561.
93. Lee N, Geraghty DE HLA-F surface expression on B cell and monocyte cell lines is partially independent from tapasin and completely independent from TAP. J Immunol 2003, 171:5264-5271.
94. Boyle LH, Gillingham AK, Munro S, Trowsdale J Selective export of HLA-F by its cytoplasmic tail. J Immunol 2006, 176:6464-6472.
95. Munz C, Nickolaus P, Lammert E, et al. The role of peptide presentation in the physiological function of HLA-G. Cancer Biol 1999, 9:47-54.
96. Clements CS, Kjer-Nielsen L, Kostenko L, et al. Crystal structure of HLA-G: a nonclassical MHC class I molecule expressed at the fetal-maternal interface. Proc Natl Acad Sci USA 2005, 102:3360-3365.
97. Apps R, Gardner L, Moffett A A critical look at HLA-G. Trends Immunol 2008, 29:313-321.
98. Shiroishi M, Kuroki K, Rasubala L, et al. Structural basis for recognition of the nonclassical MHC molecule HLA-G by the leukocyte Ig-like receptor B2 . Proc Natl Acad Sci U S A 2006, 103:16412-16417.
99. Apps R, Gardner L, Sharkey AM, et al. A homodimeric complex of HLA-G on normal trophoblast cells modulates antigen-presenting cells via LILRB1. Eur J Immunol 2007, 37:1924-1937.
100. Rajagopalan S, Bryceson YT, Kuppusamy SP, et al. Activation of NK cells by an endocytosed receptor for soluble HLA-G. PLoS Biol 2006, 4:e9.
101. Bahram S MIC genes: from genetics to biology. Adv Immunol 2000, 76:1-60.
102. Bahram S, Inoko H, Shiina T, Radosavljevic M MIC and other NKG2D ligands: from none to too many. Curr Opin Immunol 2005, 17:505-509.
103. Collins RW Human MHC class I chain related genes: their biological function and relevance to disease and transplantation. Eur J Immunogenet 2004, 31:105-114.
104. Li P, Willie ST, Bauer S, et al. Crystal structure of the MHC class I homolog MIC-A, a gamma/delta T cell ligand. Immunity 1999, 10:577-584.
105. Seliger B, Abken H, Ferrone S HLA-G and MIC expression in tumors and their role in anti-tumor immunity. Trends Immunol 2003, 24:82-87.
106. Suarez-Alvarez B, Lopez-Vazquez A, Baltar JM, et al. Potential role of NKG2D and its ligands in organ transplantation: new target for immunointervention. Am J Transplant 2009, 9:251-257.
107. Zou Y, Stastny P The role of major histocompatibility complex class I chain-related gene A antibodies in organ transplantation. Curr Opin Organ Transplant 2009, 14:414-418.
108. Silk JD, Salio M, Brown J, et al. Structural and functional aspects of lipid binding by CD1 molecules. Annu Rev Cell Dev Biol 2008, 24:369-395.
109. Lawton AP, Kronenberg M The third way: progress on pathways of antigen processing and presentation by CD1. Immunol Cell Biol 2004, 82:295-306.
110. Cohen NR, Garg S, Brenner MB Antigen presentation by CD1 lipids, T cells, and NKT cells in microbial immunity. Adv Immunol 2009, 102:1-94.
111. Simpson E, Scott D, James E, et al. Minor H antigens: genes and peptides. Transpl Immunol 2002, 10:115-123.
112. Hambach L, Spierings E, Goulmy E Risk assessment in haematopoietic stem cell transplantation: minor histocompatibility antigens. Best Pract Res Clin Haematol 2007, 20:171-187.
113. Goulmy E Minor histocompatibility antigens: from transplantation problems to therapy of cancer. Hum Immunol 2006, 67:433-438.
114. Spierings E, Hendriks M, Absi L, et al. Phenotype frequencies of autosomal minor histocompatibility antigens display significant differences among populations. PLoS Genetics 2007, 3:e103.
115. Falkenburg JH, van de Corput L, Marijt EW, Willemze R Minor histocompatibility antigens in human stem cell transplantation. Exp Hematol 2003, 31:743-751.
116. Lanier LL NK cell recognition. Annu Rev Immunol 2005, 23:225-274.
117. Bryceson YT, March ME, Ljunggren HG, Long EO Activation, coactivation, and costimulation of resting human natural killer cells. Immunol Rev 2006, 214:73-91.
118. Bashirova AA, Martin MP, McVicar DW, Carrington M The killer immunoglobulin-like receptor gene cluster: tuning the genome for defense. Annu Rev Genomics Hum Genet 2006, 7:277-300.
119. Colonna M, Spies T, Strominger JL, et al. Alloantigen recognition by two human natural killer cell clones is associated with HLA-C or a closely linked gene. Proc Natl Acad Sci USA 1992, 89:7983-7985.
120. Mandelboim O, Reyburn HT, Vales-Gomez M, et al. Protection from lysis by natural killer cells of group 1 and 2 specificity is mediated by residue 80 in human histocompatibility leukocyte antigen C alleles and also occurs with empty major histocompatibility complex molecules. J Exp Med 1996, 184:913-922.
121. Trowsdale J Genetic and functional relationships between MHC and NK receptor genes. Immunity 2001, 15:363-374.
122. Hsu KC, Chida S, Dupont B, Geraghty DE The killer cell immunoglobulin-like receptor genomic region: gene-order, haplotypes and allelic polymorphism. Immunological Reviews 2002, 190:40-52.
123. Robinson J, Waller MJ, Stoehr P, Marsh SG IPD - the Immuno Polymorphism Database. Nucleic Acids Res 2005, 33:D523-D526.
124. Yawata M, Yawata N, Draghi M, et al. Roles for HLA and KIR polymorphisms in natural killer cell repertoire selection and modulation of effector function. J Exp Med 2006, 203:633-645.
125. Andersson S, Fauriat C, Malmberg JA, et al. KIR acquisition probabilities are independent of self-HLA class I ligands and increase with cellular KIR expression. Blood 2009, 114:95-104.
126. Jonsson AH, Yokoyama WM Natural killer cell tolerance licensing and other mechanisms. Adv Immunol 2009, 101:27-79.
127. Brodin P, Karre K, Hoglund P NK cell education: not an on-off switch but a tunable rheostat. Trends Immunol 2009, 30:143-149.
128. Ruggeri L, Capanni M, Urgani E, et al. Effectiveness of donor natural killer cell alloreactivity in mismatched hematopoietic transplants. Science 2002, 295:2097-2100.
129. Witt CS The influence of NK alloreactivity on matched unrelated donor and HLA identical sibling haematopoietic stem cell transplantation. Curr Opin Immunol 2009, 21:531-537.
130. Grzywacz B, Miller JS, Verneris MR Use of natural killer cells as immunotherapy for leukaemia. Best Pract Res Clin Haematol 2008, 21:467-483.
131. Passweg JR, Huard B, Tiercy JM, Roosnek E HLA and KIR polymorphisms affect NK-cell anti-tumor activity. Trends Immunol 2007, 28:437-441.
132. Borrego F, Masilamani M, Marusina AI, et al. The CD94/NKG2 family of receptors: from molecules and cells to clinical relevance. Immunol Res 2006, 35:263-278.
133. Sullivan LC, Clements CS, Beddoe T, et al. The heterodimeric assembly of the CD94-NKG2 receptor family and implications for human leukocyte antigen-E recognition. Immunity 2007, 27:900-911.
134. Burgess SJ, Maasho K, Masilamani M, et al. The NKG2D receptor: immunobiology and clinical implications. Immunol Res 2008, 40:18-34.
135. Lopez-Larrea C, Suarez-Alvarez B, Lopez-Soto A, et al. The NKG2D receptor: sensing stressed cells. Trends Mol Med 2008, 14:179-189.
136. Brown D, Trowsdale J, Allen R The LILR family: modulators of innate and adaptive immune pathways in health and disease. Tissue Antigens 2004, 64:215-225.
137. Anderson KJ, Allen RL Regulation of T-cell immunity by leucocyte immunoglobulin-like receptors: innate immune receptors for self on antigen-presenting cells. Immunology 2009, 127:8-17.
138. Katz HR Inhibition of inflammatory responses by leukocyte Ig-like receptors. Adv Immunol 2006, 91:251-272.
139. American Society of Histocompatibility and Immunogenetics Laboratory Manual. 4.2 ed. 2008.
140. Reinsmoen NL, Zeevi A Evaluation of the cellular immune response in transplantation. Manual of Molecular and Clinical Laboratory Immunology 2006, 1228-1243. ASM Press, Washington DC. B. Detrick, R.G. Hamilton, J.D. Folds .
141. Mickelson EM, Longton G, Anasetti C, et al. Evaluation of the mixed lymphocyte culture assay as a method for selecting unrelated donors for marrow transplantation. Tissue Antigens 1996, 47:27-36.
142. Spencer A, Szydlo RM, Brookes PA, et al. Bone marrow transplantation for chronic myeloid leukemia with volunteer unrelated donors using ex vivo or in vivo T-cell depletion: major prognostic impact of HLA class I identity between donor and recipient. Blood 1995, 86:3590-3597.
143. Wang XN, Taylor PR, Skinner R, et al. T-cell frequency analysis does not predict the incidence of graft-versus-host disease in HLA-matched sibling bone marrow transplantation. Transplantation 2000, 70:488-493.
144. Sayer DC, Smith LK, Krueger R, Chrisitansen FT DNA sequencing-based HLA typing detects a B-cell ALL blast-specific mutation in HLA-A2402 resulting in loss of HLA allele expression. Leukemia 2004, 18:174-176.
145. Jacobbi LM, Blackwell P Guidelines for specimen collection, storage and transportation. ASHI Laboratory Manual 2000, American Society for Histocompatibility and Immunogenetics. A.B. Hahn, G.A. Land, R.M. Strothman .
146. Schaffer M, Olerup O HLA-AB typing by polymerase-chain reaction with sequence-specific primers: more accurate, less errors, and increased resolution compared to serological typing. Tissue Antigens 2001, 58:299-307.
147. Welsh K, Bunce M Molecular typing for the MHC with PCR-SSP. Rev Immunogenetics 1999, 1:157-176.
148. Kimura A, Dong RP, Harada H, Sasazuki T DNA typing of HLA class II genes in B-lymphoblastoid cell lines homozygous for HLA. Tissue Antigens 1992, 40:5-12.
149. Cao K, Chopek M, Fernandez-Vina MA High and intermediate resolution DNA typing systems for class I HLA-A, -B, -C genes by hybridization with sequence specific oligonucleotide probes . Rev. Immunogenetics 1999, 1:177-208.
150. Scheltinga SA, Johnston-Dow LA, White CB, et al. A generic sequencing based typing approach for the identification of HLA-A diversity. Hum Immunol 1997, 57:120-128.
151. McGinnis MD, Conrad MP, Bouwens AGM, et al. Automated, solid-phase sequencing of DRB region genes using T7 sequencing chemistry and dye-labeled primers. Tissue Antigens 1995, 46:173-179.
152. Zachary AA, Houp JA, Vega R, et al. Evaluation of the humoral response in transplantation. Manual of Molecular and Clinical Laboratory Immunology 2006, 1215-1227. ASM Press, Washington, DC. B. Detrick, R.G. Hamilton, J.D. Folds .
153. Fulton RJ, McDade RL, Smith PL, et al. Advanced multiplexed analysis with the FlowMetrix system. Clinical Chemistry 1997, 43:1749-1756.
154. Mickelson EM, Petersdorf E, Anasetti C, et al. HLA matching in hematopoietic cell transplantation. Hum Immunol 2000, 61:92-100.
155. Ottinger HD, Rebmann V, Pfeiffer KA, et al. Positive serum crossmatch as predictor for graft failure in HLA-mismatched allogeneic blood stem cell transplantation. Transplantation 2002, 73:1280-1285.
156. Van Den Boogaardt DE, van Rood JJ, Roelen DL, Claas FH The influence of inherited and noninherited parental antigens on outcome after transplantation. Transpl Int 2006, 19:360-371.
157. Wan AM, Ennis PD, Parham P, Holmes N The primary structure of HLA-A32 suggests a region involved in formation of the Bw4/Bw6 epitopes. J Immunol 1986, 137:3671-3674.
158. Toubert A, Raffoux C, Boretto J, et al. Epitope mapping of HLA-B27 and HLA-B7 antigens by using intradomain recombinants. J Immunol 1988, 141:2503-2509.
159. Rodey GE, Fuller TC Public epitopes and the antigenic structure of the HLA molecules. Crit Rev Immunol 1987, 7:229-267.
160. Rodey GE, Neylan JF, Whelchel JD, et al. Epitope specificity of HLA class I alloantibodies. I. Frequency analysis of antibodies to private versus public specificities in potential transplant recipients. Hum Immunol 1994, 39:272-280.
161. Rodey GE HLA Beyond Tears 2000, De Novo, Durango CO. 2nd ed.
162. Thompson JS, Thacker LR CREG matching for first cadaveric kidney transplants performed by SEOPF centers between October 1987 and September 1995. Southeastern Organ Procurement Foundation. Clin Transplant 1996, 10:586-593.
163. Takemoto SK, Cecka JM, Terasaki PI Benefits of HLA-CREG matching for sensitized recipients as illustrated in kidney regrafts. Transplant Proc 1997, 29:1417.
164. Wade JA, Hurley CK, Takemoto SK, et al. HLA mismatching within or outside of cross-reactive groups is associated with similar outcomes after unrelated hematopoietic stem cell transplantation. Blood 2007, 109:4064-4070.
165. Duquesnoy R, Spellman S, Haagenson M, et al. HLAMatchmaker-defined triplet matching is not associated with better survival rates of patients with class I HLA allele mismatched hematopoietic cell transplants from unrelated donors. Biol Blood Marrow Transplant 2008, 14:1064-1071.
166. Noreen HJ, Yu N, Setterholm M, et al. Validation of DNA-based HLA-A and HLA-B testing of volunteers for a bone marrow registry through parallel testing with serology. Tissue Antigens 2001, 57:221-229.
167. Bochtler W, Maiers M, Oudshoorn M, et al. World Marrow Donor Association guidelines for use of HLA nomenclature and its validation in the data exchange among hematopoietic stem cell donor registries and cord blood banks. Bone Marrow Transplant 2007, 39:737-741.
168. Hurley CK Acquisition and use of DNA-based HLA typing data in bone marrow registries. Tissue Antigens 1997, 49:323-328.
169. Holdsworth R, Hurley CK, Marsh SG, et al. The HLA dictionary 2008: a summary of HLA-A, -B, -C, -DRB1/3/4/5, and -DQB1 alleles and their association with serologically defined HLA-A, -B, -C, -DR, and -DQ antigens. Tissue Antigens 2009, 73:95-170.
170. Sollid LM Coeliac disease: dissecting a complex inflammatory disorder. Nat Rev Immunol 2002, 2:647-655.
171. Chessman D, Kostenko L, Lethborg T, et al. Human leukocyte antigen class I-restricted activation of CD8+ T cells provides the immunogenetic basis of a systemic drug hypersensitivity. Immunity 2008, 28:822-832.
172. Opelz G, Dohler B Effect of human leukocyte antigen compatibility on kidney graft survival: comparative analysis of two decades. Transplantation 2007, 84:137-143.
173. Takemoto SK, Zeevi A, Feng S, et al. National conference to assess antibody-mediated rejection in solid organ transplantation. Am J Transplant 2004, 4:1033-1041.
174. Zachary AA, Montgomery RA, Leffell MS Defining unacceptable HLA antigens. Curr Opin Organ Transplant 2008, 13:405-410.
175. Hod E, Schwartz J Platelet transfusion refractoriness. Br J Haematol 2008, 142:348-360.
176. Thomas ED A history of haematopoietic cell transplantation. Br J Haematol 1999, 105:330-339.
177. O'Reilly RJ, Dupont B, Pahwa S, et al. Reconstitution in severe combined immundeficiency by transplantation of marrow from an unrelated donor. N Engl J Med 1977, 297:1311-1318.
178. Hurley CK, Raffoux C World Marrow Donor Association: international standards for unrelated hematopoietic stem cell donor registries. Bone Marrow Transplant 2004, 34:103-110.
179. Gahrton G, van Rood JJ, Oudshoorn M The World Marrow Donor Association : its goals and activities. Bone Marrow Transplant 2003, 32:121-124.
180. Ljungman P, Urbano-Ispizua A, Cavazzana-Calvo M, et al. Allogeneic and autologous transplantation for haematological diseases, solid tumours and immune disorders: definitions and current practice in Europe. Bone Marrow Transplant 2006, 37:439-449.
181. Schipper RF, D'Amaro J, Oudshoorn M The probability of finding a suitable related donor for bone marrow transplantation in extended families . Blood 1996, 87:800-804.
182. Koh LP, Chao N Haploidentical hematopoietic cell transplantation. Bone Marrow Transplant 2008, 42:S60-S63.
183. Oudshoorn M, van Leeuwen A, v.d.Zanden HG, van Rood JJ Bone Marrow Donors Worldwide: a successful exercise in international cooperation. Bone Marrow Transplant 1994, 14:3-8.
184. Bray RA, Hurley CK, Kamani NR, et al. National marrow donor program HLA matching guidelines for unrelated adult donor hematopoietic cell transplants. Biol Blood Marrow Transplant 2008, 14:45-53.
185. Kamani N, Spellman S, Hurley CK, et al. State of the art review: HLA matching and outcome of unrelated donor umbilical cord blood transplants. Biol Blood Marrow Transplant 2008, 14:1-6.